Top Suppliers:I want be here

170212-26-7

170212-26-7 structure
170212-26-7 structure
  • Name: C6 NBD Galactosylceramide (d18:1/6:0)
  • Chemical Name: N-[(2S,3R,4E)-1-(β-D-Galactopyranosyloxy)-3-hydroxy-4-octadecen-2-yl]-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanamide
  • CAS Number: 170212-26-7
  • Molecular Formula: C36H59N5O11
  • Molecular Weight: 737.881
  • Catalog: Research Areas Others
  • Create Date: 2018-01-28 07:31:53
  • Modify Date: 2023-01-15 16:38:20
  • C6 NBD galactosylceramide is an active derivative of galactosylceramide that is tagged with fluorescent C6 nitrobenzoxadiazole (C6 NBD). C6 NBD galactosylceramide can be used as a substrate for neutral β-glycosylceramidase (GCase) to study intracellular localization and metabolism of galactosylceramide (Ex=nm, Em=525)[1].

Name N-[(2S,3R,4E)-1-(β-D-Galactopyranosyloxy)-3-hydroxy-4-octadecen-2-yl]-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanamide
Synonyms Hexanamide, N-[(1S,2R,3E)-1-[(β-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-
N-[(2S,3R,4E)-1-(β-D-Galactopyranosyloxy)-3-hydroxy-4-octadecen-2-yl]-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanamide
Description C6 NBD galactosylceramide is an active derivative of galactosylceramide that is tagged with fluorescent C6 nitrobenzoxadiazole (C6 NBD). C6 NBD galactosylceramide can be used as a substrate for neutral β-glycosylceramidase (GCase) to study intracellular localization and metabolism of galactosylceramide (Ex=nm, Em=525)[1].
Related Catalog
In Vitro C6-NBD-glucosylceramide (4 μM) is transported to the Golgi apparatus in HT29 cells[1]. Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs)[2]. Transcytosis of Exogenous C6-NBD-GaICer after Endocytosis: 1. C6-NBD-glucosylceramide is inserted at 10°C. 2. Cells are rinsed three times with cold HBSS' and incubated at 37°C in HBSS' to allow endocytosis. 3. After 10 min, the probe remaining on the cell surface is removed by two (apical) or three (basal) BSA washes for 20 min at 10°C. 4. One set of filters is used for lipid analysis to quantitate endocytosis. A second set of filters is further incubated for 0.5 or 1 h at 37°C in HBSS' + BSA, to assay for reappearance of intracellular C6-NBD-glucosylceramide on either cell surface. 5. The incubations are followed by a 10°C BSA wash, after which the NBD lipids from the combined apical media, basal media, and the cells were extracted into chloroform/methanol, analyzed by TLC, and quantitated.
References

[1]. J W Kok, et al. Sorting of sphingolipids in the endocytic pathway of HT29 cells. J Cell Biol. 1991 Jul;114(2):231-9.

[2]. I van Genderen, et al. Differential targeting of glucosylceramide and galactosylceramide analogues after synthesis but not during transcytosis in Madin-Darby canine kidney cells. J Cell Biol. 1995 Nov;131(3):645-54.

Density 1.3±0.1 g/cm3
Molecular Formula C36H59N5O11
Molecular Weight 737.881
Exact Mass 737.421082
LogP 6.14
Index of Refraction 1.585